[对刺激性肠综合征长期使用益生菌:法律要求]
O I Solovyeva1, A S Nekrasova1, I G Topalova1
1Mechnikov North-Western State Medical University.
Terapevticheskii arkhiv
|December 30, 2023
概括
长达12周的益生菌Bifidobacterium longum 35624®疗程显著改善了患有刺激性肠综合征 (IBS) 的患者的症状和生活质量. 这种延长疗法表现出持久的积极效果,即使在治疗停止后.
科学领域:
- 胃肠病学 胃肠病学
- 微生物学 微生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 刺激性肠综合征 (IBS) 是一种普遍存在的功能性胃肠疾病.
- 肠道失生症与IBS的发病有关.
- 益生菌菌株Bifidobacterium longum 35624®因其在IBS治疗中的有效性而得到认可.
研究的目的:
- 为了评估Bifidobacterium longum 35624®延长12周疗程与IBS患者的标准持续时间相比的疗程的疗效.
- 评估延长益生菌治疗对IBS症状严重程度和生活质量的影响.
主要方法:
- 一项观察性研究涉及42名IBS患者 (中度至重度).
- 患者接受了Bifidobacterium longum 35624® (1×10^9 CFU/天) 的治疗,持续了12周.
- 症状评估包括VAS,VSI,IBS-SSS和IBS-QoL,在多个时间点进行评估,包括治疗后.
主要成果:
- Bifidobacterium longum 35624®显著减少了腹部疼痛,胀气和便不规则.
- 观察到IBS症状严重程度显著降低 (IBS-SSS) 和改善生活质量 (IBS-QoL).
- 最显著的改善发生在第12周,停药一个月后持续影响,包括对内脏敏感性的"后益生菌"影响.
结论:
- 长达12周的Bifidobacterium longum 35624®疗程可以增强IBS患者的治疗效果.
- 该研究表明持续的"后益生菌"效果,表明持久的益处.
- 这种益生菌的重复疗程被建议用于管理IBS的慢性,复发性.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
172
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
172
Irritable Bowel Syndrome III: Medical and Nursing Management
208
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
208
Drugs for Treatment of Diarrhea-Predominant IBS
177
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
177
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
334
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
334
Irritable Bowel Syndrome I: Introduction
277
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
277
Inflammatory Bowel Disease IV: Pharmacological Management
128
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
128


